Characteristics of rare-aberrations group
No. . | Karyotype . | Sex . | Age, y . | WBC, × 109/L . | % BM blasts . | Response to induction . | DFS, mo . | OS, mo . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Abnormalities reported previously to confer adverse prognosis in AML | ||||||||||
| 1 | 46,XX,t(6;9)(p23;q34)[19]/46,XX[1] | F | 62 | 25 | 56 | CR | 3 | 11 | ||
| 2 | 46,XY,t(9;22)(q34;q11.2)[29]/46,XY[2] | M | 60 | 106 | 65 | R | NA | 12 | ||
| 3 | 46,XX,t(9;22)(q34;q11.2)[29]/46,XX[1] | F | 63 | 25 | 84 | CR | 2 | 8 | ||
| 4 | 46,XX,t(5;9;22)(p31;q34;q11.2)[20] | F | 72 | 112 | 48 | R | NA | 3 | ||
| 5 | 46,XX,t(3;21)(q26;q22)[3] | F | 79 | — | 36 | CR | 8 | 12 | ||
| 6 | 46,XX,t(2;3)(p21;q27)[28] | F | 66 | 110 | 79 | R | NA | 5 | ||
| 7 | 46,XY,del(3)(q13.2q27)[15]/46,XY[7] | M | 67 | 17 | 40 | R | NA | 25 | ||
| 8 | 46,XY,add(3)(q12),del(16)(q22q24)[19]/46,XY[1] | M | 83 | 1 | — | D | NA | <1 | ||
| 9 | 47,XX,+4[13]/46,XX[27] | F | 65 | 11 | 72 | D | NA | <1 | ||
| 10 | 47,XX,+4[26]/46,XX[6] | F | 68 | 2 | 65 | D | NA | <1 | ||
| 11 | 47,XX,+4[5]/46,XX[15] | F | 79 | 9 | 55 | CR | 7 | 10 | ||
| 12 | 47,XY,+i(11)(q10)[20] | M | 68 | 47 | 89 | R | NA | 21 | ||
| 13 | 46,XY,i(13)(q10)[8]/46,XY[12] | M | 77 | 188 | 87 | R | NA | 1 | ||
| 14 | 46,XX,+2-17dmin[23]/47,XX,+r,+3-24dmin[4] | F | 76 | 9 | 77 | R | NA | 15 | ||
| Abnormalities with thus far unknown prognostic significance in AML | ||||||||||
| 15 | 45,XY,−10[5]/46,XY[24] | M | 67 | 46 | 88 | D | NA | <1 | ||
| 16 | 47,XX,+15[14]/46,XX[14] | F | 62 | 1 | 45 | CR | 5 | 14 | ||
| 17 | 47,XY,+20[12]/46,XY[18] | M | 73 | 30 | 79 | R | NA | 2 | ||
| 18 | 46,XY,del(2)(p21)[13]/46,XY[7] | M | 62 | 4 | 76 | D | NA | <1 | ||
| 19 | 46,XY,add(2)(p23)[3]/46,XY[22] | M | 70 | 6 | 56 | CR | 18 | 51 | ||
| 20 | 46,XX,del(14)(q?13q?22)[3]/46,XX[50] | F | 73 | 1 | 54 | CR | 19 | 24 | ||
| 21 | 46,XY,t(4;14;8)(p16;q1?1.2;p21)[37] | M | 66 | 53 | 80 | D | NA | <1 | ||
| 22 | 46,XX,der(15)t(1;15)(q11;p13)[44]/46,XX[1] | F | 62 | 81 | 96 | D | NA | <1 | ||
| 23 | 46,XX,der(18)t(1;18)(q25;q23)[20]/46,XX[1] | F | 66 | 133 | 97 | D | NA | <1 | ||
| 24 | 47,XY,+der(1;19)(q10;p10)[20] | M | 68 | 106 | 60 | R | NA | 4 | ||
| 25 | 46,XX,t(9;13)(q21.1;q33)[23] | F | 65 | 5 | 31 | D | NA | <1 | ||
| 26 | 46,XX,?dup(9)(q13q22)[20] | F | 71 | 89 | 86 | D | NA | <1 | ||
| 27 | 46,X,del(Y)(q12)[20]/46,XY[6] | M | 64 | 1 | 69 | D | NA | <1 | ||
| 28 | 46,XY,t(6;12)(q11;p11.2)[20] | M | 71 | 51 | 84 | R | NA | 1 | ||
| 29 | 46,XY,del(8)(q2?2q2?4.1)[20] | M | 78 | 6 | 50 | CR | 9 | 12 | ||
| 30 | 46,XY,add(13)(p11)[19]/46,XY[1] | M | 66 | 2 | 76 | R | NA | 11 | ||
| 31 | 46,XX,del(16)(q12.1)[16]/46,XX[14] | F | 67 | 3 | 62 | CR | 17 | 28 | ||
| 32 | 47,XX,+r[7]/48,XX,+2r[23] | F | 70 | 49 | 76 | CR | 16 | 22 | ||
| 33 | 47,XY,+mar[5]/46,XY[35] | M | 67 | 4 | 35 | R | NA | 27 | ||
No. . | Karyotype . | Sex . | Age, y . | WBC, × 109/L . | % BM blasts . | Response to induction . | DFS, mo . | OS, mo . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Abnormalities reported previously to confer adverse prognosis in AML | ||||||||||
| 1 | 46,XX,t(6;9)(p23;q34)[19]/46,XX[1] | F | 62 | 25 | 56 | CR | 3 | 11 | ||
| 2 | 46,XY,t(9;22)(q34;q11.2)[29]/46,XY[2] | M | 60 | 106 | 65 | R | NA | 12 | ||
| 3 | 46,XX,t(9;22)(q34;q11.2)[29]/46,XX[1] | F | 63 | 25 | 84 | CR | 2 | 8 | ||
| 4 | 46,XX,t(5;9;22)(p31;q34;q11.2)[20] | F | 72 | 112 | 48 | R | NA | 3 | ||
| 5 | 46,XX,t(3;21)(q26;q22)[3] | F | 79 | — | 36 | CR | 8 | 12 | ||
| 6 | 46,XX,t(2;3)(p21;q27)[28] | F | 66 | 110 | 79 | R | NA | 5 | ||
| 7 | 46,XY,del(3)(q13.2q27)[15]/46,XY[7] | M | 67 | 17 | 40 | R | NA | 25 | ||
| 8 | 46,XY,add(3)(q12),del(16)(q22q24)[19]/46,XY[1] | M | 83 | 1 | — | D | NA | <1 | ||
| 9 | 47,XX,+4[13]/46,XX[27] | F | 65 | 11 | 72 | D | NA | <1 | ||
| 10 | 47,XX,+4[26]/46,XX[6] | F | 68 | 2 | 65 | D | NA | <1 | ||
| 11 | 47,XX,+4[5]/46,XX[15] | F | 79 | 9 | 55 | CR | 7 | 10 | ||
| 12 | 47,XY,+i(11)(q10)[20] | M | 68 | 47 | 89 | R | NA | 21 | ||
| 13 | 46,XY,i(13)(q10)[8]/46,XY[12] | M | 77 | 188 | 87 | R | NA | 1 | ||
| 14 | 46,XX,+2-17dmin[23]/47,XX,+r,+3-24dmin[4] | F | 76 | 9 | 77 | R | NA | 15 | ||
| Abnormalities with thus far unknown prognostic significance in AML | ||||||||||
| 15 | 45,XY,−10[5]/46,XY[24] | M | 67 | 46 | 88 | D | NA | <1 | ||
| 16 | 47,XX,+15[14]/46,XX[14] | F | 62 | 1 | 45 | CR | 5 | 14 | ||
| 17 | 47,XY,+20[12]/46,XY[18] | M | 73 | 30 | 79 | R | NA | 2 | ||
| 18 | 46,XY,del(2)(p21)[13]/46,XY[7] | M | 62 | 4 | 76 | D | NA | <1 | ||
| 19 | 46,XY,add(2)(p23)[3]/46,XY[22] | M | 70 | 6 | 56 | CR | 18 | 51 | ||
| 20 | 46,XX,del(14)(q?13q?22)[3]/46,XX[50] | F | 73 | 1 | 54 | CR | 19 | 24 | ||
| 21 | 46,XY,t(4;14;8)(p16;q1?1.2;p21)[37] | M | 66 | 53 | 80 | D | NA | <1 | ||
| 22 | 46,XX,der(15)t(1;15)(q11;p13)[44]/46,XX[1] | F | 62 | 81 | 96 | D | NA | <1 | ||
| 23 | 46,XX,der(18)t(1;18)(q25;q23)[20]/46,XX[1] | F | 66 | 133 | 97 | D | NA | <1 | ||
| 24 | 47,XY,+der(1;19)(q10;p10)[20] | M | 68 | 106 | 60 | R | NA | 4 | ||
| 25 | 46,XX,t(9;13)(q21.1;q33)[23] | F | 65 | 5 | 31 | D | NA | <1 | ||
| 26 | 46,XX,?dup(9)(q13q22)[20] | F | 71 | 89 | 86 | D | NA | <1 | ||
| 27 | 46,X,del(Y)(q12)[20]/46,XY[6] | M | 64 | 1 | 69 | D | NA | <1 | ||
| 28 | 46,XY,t(6;12)(q11;p11.2)[20] | M | 71 | 51 | 84 | R | NA | 1 | ||
| 29 | 46,XY,del(8)(q2?2q2?4.1)[20] | M | 78 | 6 | 50 | CR | 9 | 12 | ||
| 30 | 46,XY,add(13)(p11)[19]/46,XY[1] | M | 66 | 2 | 76 | R | NA | 11 | ||
| 31 | 46,XX,del(16)(q12.1)[16]/46,XX[14] | F | 67 | 3 | 62 | CR | 17 | 28 | ||
| 32 | 47,XX,+r[7]/48,XX,+2r[23] | F | 70 | 49 | 76 | CR | 16 | 22 | ||
| 33 | 47,XY,+mar[5]/46,XY[35] | M | 67 | 4 | 35 | R | NA | 27 | ||
WBC indicates white blood cell count; BM, bone marrow; F, female; CR, complete remission; M, male; R, primary resistant disease; NA, not applicable; —, not available; and D, induction death.